Biotechnology investor, Peter Kolchinsky, joins the State of Health to talk with Gunnar about drug pricing. The conversation covers the long term view that when drugs go generic without undue delay, the value they provide to society is far greater than the short-run value that cost effectiveness analyses often show, which Peter details in his book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines. Peter also talks about his new non-profit, No Patient Left Behind, of which Gunnar is a part, and why out of pocket costs should be seen as the true barriers between innovative medicines and patients. Peter uses the COVID-19 pandemic as a case study for improving access issues insofar that out of pocket costs were largely eliminated for vaccines. No Patient Left behind is on twitter @NPLB_org and on the web at www.nopatientleftbehind.org
State of Health Episode 8: Drug Pricing, Valuing Innovation and No Patient Left Behind with Peter Kolchinsky
